---
title: "Vera Therapeutics, Inc. (VERA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VERA.US.md"
symbol: "VERA.US"
name: "Vera Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:44:30.339Z"
locales:
  - [en](https://longbridge.com/en/quote/VERA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VERA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VERA.US.md)
---

# Vera Therapeutics, Inc. (VERA.US)

## Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [veratx.com](https://veratx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -6.46 | 406 | - | - | - |
| PB | 4.77 | 323 | 7.34 | 4.40 | 2.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **14**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 12 | 86% |
| Overweight | 1 | 7% |
| Hold | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.25 |
| Highest Target | 110.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VERA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VERA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VERA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VERA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**